Bioniz is a clinical-stage therapeutics company transforming drug development for immune-driven diseases by focusing on the selective modulation of multiple cytokines, the primary mediators of the immune system. Our proprietary technology, called Multi Modal Modulation (M3), has enabled the rational design of next generation anti-cytokine therapeutics that can selectively inhibit multiple cytokines as a single therapeutic agent while maintaining the normal functionality of the immune system.
Bioniz Therapeutics has been aquired by Equillium, Inc.
Bioniz Therapeutics
Seeking to balance the immune system for those suffering from auto-immune and immune dysregulation diseases
TARGETED THERAPEUTICS DESIGNED TO INHIBIT MULTIPLE DISEASE SIGNALS
BNZ-1 in T-Cell Mediated Diseases
BNZ-1 is a selective multi-cytokine inhibitor of IL-2, IL-9, and IL-15, which are implicated in several T-cell mediated diseases. The dysregulation of these three cytokines is linked to alopecia areata, rheumatoid arthritis, vitiligo and T-cell malignancies including cutaneous T-cell lymphoma (CTCL) and many other diseases.
VIEW MORE
BNZ-1 in Cutaneous T-cell Lymphoma (CTCL)
CTCL is a rare, progressive form of non-Hodgkin’s lymphoma and is generally considered incurable with currently available therapies. Our clinical data of BNZ-1 for the treatment of CTCL shows meaningful clinical impact and improvement over standard of care.
VIEW MORE
BNZ-1 in Alopecia Areata
Alopecia areata is an immune-mediated hair loss that afflicts more than 500,000 people annually, making it amongst the most common autoimmune disorders in the U.S. There is no FDA-approved therapy for alopecia areata. Data in preclinical models strongly support the development of BNZ-1 to treat alopecia areata, and Bioniz has an IND open for a Phase 2 study.
VIEW MORE
BNZ-2 for the Treatment of Inflammatory Diseases of the GI Tract
BNZ-2 is a multi-cytokine inhibitor of IL-15 and IL-21. These two cytokines are implicated in a number of diseases such as IBD, Celiac Disease, Type I diabetes, NASH. BNZ-2 is ready for a phase 1 clinical trial. BNZ-3 is an inhibitor of IL-15 and IL-21 and is designed as an orally bioavailable drug that remains stable in stomach and intestinal fluid.
VIEW MORE
M3 Technology: Multi Modal Modulation
Bioniz’s M3 Technology Platform incorporates in silico machine learning techniques and synthesizes our deep understanding of cytokine biology, and the unique features of peptides, to create a new class of therapeutics that specifically inhibit multiple cytokines within a family simultaneously, while leaving the rest of the immune signaling network of the family intact. Many immune-mediated diseases are driven by the same combination of dysregulated cytokines, and we believe identifying the key cytokines for these diseases will allow us to target and develop customized treatment strategies for multiple autoimmune diseases with each rationally designed next-generation peptide.
VIEW MORE
